理解早期乳腺癌辅助 CDK4/6 抑制剂的临床试验结果分歧。
Understanding divergent trial results of adjuvant CDK4/6 inhibitors for early stage breast cancer.
机构信息
Breast Unit, The Royal Marsden Hospital, London, UK.
Breast Unit, The Royal Marsden Hospital, London, UK; Ralph Lauren Centre for Breast Cancer Research, The Royal Marsden Hospital, London, UK; Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.
出版信息
Cancer Cell. 2021 Mar 8;39(3):307-309. doi: 10.1016/j.ccell.2021.02.011.
CDK4/6 inhibitors have transformed the treatment of metastatic estrogen-receptor-positive HER2-negative breast cancer, with efficacy found consistently for three different inhibitors. Recent adjuvant trials of CDK4/6 inhibitors in early stage breast cancer have produced discordant results, shedding light on their clinical utility and future trial design.
CDK4/6 抑制剂改变了转移性雌激素受体阳性 HER2 阴性乳腺癌的治疗方法，三种不同的抑制剂均显示出一致的疗效。最近 CDK4/6 抑制剂在早期乳腺癌中的辅助治疗试验结果不一致，这凸显了它们的临床应用价值和未来的试验设计。
Zotero 插件